Daiwa Downgrades Pfizer (PFE) to Neutral Following Full-Year 2025 Earnings

Pfizer Inc. (NYSE:PFE) is one of the most promising low-cost stocks to buy now. On February 10, Bernstein maintained its Market Perform rating and $30 price target for Pfizer following a Q4 2o25 earnings report that exceeded expectations with $17.6 billion in revenue and $0.66 EPS. Despite strong financial results and a raised 2025 EPS guidance of $3.22, the firm remains cautious as Pfizer navigates a transitional period. Bernstein particularly highlighted that the company made some big bets, positioning ...